MicroTech Medical (Hangzhou) Co., Ltd. Class H (HK:2235) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MicroTech Medical (Hangzhou) Co., Ltd. reported a robust 36.1% increase in operating revenue for the first half of 2024, reaching RMB 150.8 million, with significant contributions from the successful launch of their new CGMS product, AiDEX X. Despite these gains, the company experienced a net loss of RMB 37.7 million, a 102.2% increase from the previous year, mainly due to higher selling expenses associated with the new product launch. However, the company successfully reduced administrative expenses by 12.7% and maintains a strong cash reserve of RMB 1.81 billion.
For further insights into HK:2235 stock, check out TipRanks’ Stock Analysis page.